PDCD1 and neoplasm: Briefly, these are monoclonal antibodies that bind specifically to the PD-1 receptor on the T-cells, as a result of this, the T-cell response is augmented or increased along the targeted tumor cells and hence, these antibodies prevent tumor cells from escaping the immune system by inhibiting the interaction between PD-1 and PD-L1 (6).